IMPORTANCE Cisplatin-induced ototoxic effects are an important complication that affects testicular cancer survivors as a consequence of treatment. The identification of genetic variants associated with this adverse drug reaction will further our mechanistic understanding of its development and potentially lead to strategies to prevent ototoxic effects.
C isplatin, a chemotherapeutic agent used in the management of several cancers, is a key component in the treatment of testicular cancer-the most common malignancy among young men. Unfortunately, the use of this drug is complicated by the development of high-frequency hearing loss, which occurs in 20% to 40% of patients with testicular cancer treated with cisplatin. 1 Studies performed in pediatric populations have enhanced our understanding of the pharmacogenetic variants involved in cisplatin-induced ototoxic effects (CIO). 2 However, whether these same genetic variants influence CIO in adult populations is unknown. The aim of this study was therefore to perform a comprehensive examination of the effects of variation in drug absorption, distribution, metabolism, and excretion (ADME) genes on the development of CIO in adult patients with testicular cancer treated with cisplatin.
Methods

Patient Cohorts and Audiological Assessments
A total of 260 patients were recruited to take part in this study. After exclusion of patients according to specified criteria (eFigure 1.1 in the Supplement), 188 patients were included in the discovery cohort from Ontario (n = 96; 23 cases and 73 controls) and replication cohort from British Columbia (n = 92; 14 cases and 78 controls). All patients were men 17 years or older who were diagnosed with germ cell testicular cancer and previously treated with cisplatin-based chemotherapy. Cisplatininduced ototoxic effects were independently diagnosed by 2 audiologists (Section 2 in the Supplement). Written informed consent was obtained from each patient and the study was approved by the ethics committee of each participating center.
Genotyping and Statistical Analyses
Samples were genotyped for 7907 variants located within ADME gene regions using a custom Illumina Infinium Panel (Illumina). Using these data, genetically determined ancestry was calculated (Section 3 in the Supplement) for inclusion in the logistic regression model, along with clinical variables that were significantly associated with CIO (Table) . All 3 models of inheritance were investigated to identify genetic variants that were significantly associated with CIO in the discovery and replication cohorts (Section 4.1 in the Supplement). These variants were prioritized for fine-mapping analyses (Section 5.1 in the Supplement) and subsequent genotyping using TaqMan Genotyping Assays (ThermoFisher Scientific). Variants associated with CIO in previous studies were extracted from PharmGKB, and association analyses were performed in the combined cohort. Statistical analyses were performed using R 3 (R Foundation) and SVS (Golden Helix Inc).
Cell Viability and Relative Gene Expression Assays
For cell viability assays, SLC16A5 gene silencing was performed in HeLa cells (Section 6.2 in the Supplement), after which cells were treated with cisplatin (316 nM-316 μM) and dissolved in phosphate buffered saline for 48 hours. Cell viability was assayed using an MTT assay (Sigma-Aldrich) and absorbance was read on a POLARstar Omega plate reader (BMG Labtech). For SLC16A5 expression experiments, HeLa cells were treated with cisplatin (0, 10, and 25 μM) for 24 hours, after which total RNA was purified for complementary DNA synthesis and subsequent quantitative polymerase chain reaction reactions (Section 6.3 in the Supplement).
Results
Genetic Association and Annotation Analyses
Association analyses identified a synonymous variant in SLC16A5, rs4788863 (p.Leu41Leu), that exerted a dominant protective effect on the development of CIO in both the discovery (odds ratio [OR], 0.05; 95% CI, 0.01-0.28; P =2.03×10 −5 ) and replication (OR, 0.02; 95% CI, 0.00-0.38; P =7 . 10×10 −4 ) cohorts (eTable 4.1 in the Supplement). This association remained significant after Bonferroni correction in the combined cohort (OR, 0.06; 95% CI, 0.02-0.22; P =2.17×10 −7 ).
These results were further substantiated through the inclusion of individuals with grade 1 CIO (n = 20), demonstrating that the frequency distribution of rs4788863 was correlated with the severity of CIO (P =8.35×10 −6 )( Figure 1 ; eTable 4.3 in the Supplement). Partitioning of the cohort according to patient ancestry and clinical characteristics revealed that rs4788863 was protective against CIO in all subanalyses (eTable 4.2 in the Supplement). Lastly, of the variants extracted from PharmGKB, only rs1695, in GSTP1, was significantly associated with CIO in the combined cohort (OR, 2.97; 95% CI, 1.02-8.66; P = .049) (eTable 4.4 in the Supplement). Annotation of variants with minor allele frequency (MAF) greater than 0.01 within the SLC16A5 gene region revealed that rs4788863 (p.Leu41Leu) was assigned the highest Combined Annotation Dependent Depletion score (13.2) indicating that this variant is predicted to be the most deleterious common variant in SLC16A5. In addition, rs4788863 was predicted to alter the rate of codon usage at this position (frequency per thousand: 39.6 for CUG vs 12.9 for UUG). One additional variant in the SLC16A5 region was prioritized for further investigation-missense variant, rs4789134 (p.Arg32Lys). However, subsequent annotation and association analyses did not support the role of this variant in the development of CIO (Section 5.2 in the Supplement).
Biological Interaction of SLC16A5 and Cisplatin In Vitro
Statistically significant (P <1.0×10 −4 ) differences in cell viability were observed between SLC16A5-silenced cells and nontargeting siRNA-treated cells, which was attributable to a larger magnitude Hill slope for SLC16A5-silenced cells (eTable 6.1 in the Supplement). In addition, expression analyses revealed that SLC16A5 was significantly induced by cisplatin in a dosedependent manner (P <1.0×10 −4 )( Figure 2 ).
Discussion
This study identified an association between a synonymous variant (rs4788863, p.Leu41Leu) in SLC16A5 and CIO (OR, 0.06; 95% CI, 0.02-0.22; P =2.17×10 −7 ). To our knowledge, this is the first study to identify a relationship between SLC16A5 and CIO, providing important insight into the biological mechanisms underlying this adverse drug reaction. There are several lines of evidence supporting the role of SLC16A5 in CIO. First, murine Slc16a5 is uniquely expressed in the cochlear and utricle hair cells, but not the surrounding cells, 3 and mutations in genes uniquely expressed in ear hair cells are likely to cause deafness. 4 Second, previous research has shown that genetic variants in other SLC genes exert protection from CIO in adult patients. 5, 6 Importantly, SLC16A5 is inhibited by ). The minor allele (T) of rs4788863 exerted a protective effect against cisplatin-induced ototoxic effects and was enriched in controls, depleted in cases experiencing moderate-to-severe cisplatin-induced ototoxic effects, and occurred at an intermediate frequency in patients experiencing mild cisplatin-induced ototoxic effects. Due to the small number of individuals with grade 2 hearing loss (n = 9), these patients were grouped with patients experiencing grade 3 hearing loss. cimetidine, 7 and the addition of cimetidine to cisplatin treatments prevented the occurrence of CIO in rat cochlear cultures and mice 8, 9 without compromising the antitumor activity of cisplatin treatment. 10 The association of rs4788863 with CIO in 2 independent cohorts was corroborated by in silico analyses, which revealed that rs4788863 is predicted to be the most deleterious common variant (MAF>0.01) in the SLC16A5 region (Combined Annotation Dependent Depletion score, 13.2), with additional annotation analyses suggesting that this variant may disrupt accurate protein translation. [11] [12] [13] [14] The evidence for a drug-gene interaction between cisplatin and SLC16A5 is strengthened by in vitro data, which demonstrate that SLC16A5 was significantly induced by cisplatin and that SLC16A5 exerts a significant impact on cisplatin-induced cell death. In addition to the novel association of SLC16A5 with CIO, we corroborated the association of a previously reported ADME variant 15 (rs1695, in GSTP1 [OR, 2.97; P = .049]). Interestingly, this is the only study listed on the curated pharmacogenomics database, PharmGKB, that matched our cohort in terms of age, sex, and cancer type (eTable 4.4 in the Supplement). These results highlight the importance of considering clinical and demographic differences in patient cohorts and highlight the need for future studies to examine the relevance of rs4788863 in other tumor types treated with cisplatin to determine whether these results extend to additional clinical scenarios.
Limitations
Although this study has played an important role in uncovering genetic risk factors for CIO in patients with testicular cancer, limitations to this study should be acknowledged. These include the retrospective case-control design, limited number of baseline audiograms and a relatively small sample size. The findings reported in this study would be strengthened by replication studies in large prospective cohorts of adult patients with testicular cancer, the use of which would also facilitate the discovery of additional genetic variants with smaller effect sizes.
Conclusions
This study identified a variant in SLC16A5 as a novel genetic risk factor for CIO in patients with testicular cancer, the validity of which was substantiated by replication in an independent cohort, supporting literature, and functional validation. The identification of this variant will inform the development of pharmacogenomic tests to predict a priori patients at higher genomic risk for CIO and guide important research into intervention strategies to mitigate hearing loss from cisplatin treatment. Role of the Funder/Sponsor: The funders/ sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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Supplementary Material
Audiological Assessments
Extensive clinical data (noise exposures, age, concomitant ototoxic medications, and timing of cisplatin treatment) and audiograms post-cisplatin treatment (median follow-up time of 32 months; interquartile range: 13-62 months) were collected for all patients. Using the criteria listed in eTable 2.1, two audiologists independently reviewed these data for case-control designation and discrepant cases were discussed and resolved by a panel of clinical experts. In cases where the data were ambiguous, patients were excluded from further analyses. Severity of cisplatin-induced ototoxicity (CIO) was graded according to the frequency at which hearing loss was observed, using modified Common Terminology Criteria for Adverse Events Version 4.03 criteria (as depicted in eFigure 2.1 and eTable 2.2). As a further quality control measure, the median hearing thresholds were compared to those of an age and gender matched normative population 2 (eFigure 2.2). The median hearing threshold at each frequency (1, 2, 3, 4, 6 and 8 kHz) was calculated for each age group included in the current study. These median thresholds were compared to the median hearing thresholds of age and gender matched populations from a previous study 2 . Measurements >25dB (red shaded areas) are considered consistent with hearing loss.
Methods
Genetically-determined ancestry was calculated using the patient genotype data in combination with corresponding genetic data available for the 1000 Genomes Project Phase 3 release data 3 . Principal component analyses were performed using EIGENSOFT v5.0 4 . Proportion genetic ancestry was assigned to each of the patient samples using ADMIXTURE 5 , including five ancestral components.
Results
ADMIXTURE analyses revealed that the proportion of European genetic ancestry was significantly different between cases and controls (P=0.03) in the combined cohort and principal component analyses revealed that all individuals of East Asian ancestry were controls, although this difference was not significant (P=0.67) (eFigure 3.1). Therefore, for both cohorts, in addition to the clinical covariates that were associated with CIO, genetically-determined European and East Asian ancestry (calculated from the ADMIXTURE analyses) were included as covariates in the genetic association analyses. Analyses were repeated excluding all East Asian individuals and including European ancestry as a covariate (eTable 4.2).
eFigure 3.1: Principal Component Analyses
Inspection of the second principal component revealed that CPNDS individuals of East Asian genetic ancestry were unequally distributed between cases and controls. This difference was however not significantly different between cases and controls (P=0.67). AFR: 1000 Genomes Project African population, AMR: 1000 Genomes Project American population; CPNDS: Canadian Pharmacogenomics Network for Drug Safety; EAS: 1000 Genomes Project East Asian population; EUR: 1000 Genomes Project European population; PC: Principal Component; SAS: 1000 Genomes Project South Asian population.
Genetic Association Analyses
Association analyses in the discovery and replication cohorts
Genomic DNA samples were genotyped for 7907 variants using a custom Illumina Infinium ADME Panel (Illumina, San Diego, CA). The genotype data were subsequently clustered using the GenomeStudio Software (Illumina) and additional sample (call rate>0.95 and genotype gender and relatedness checks) and variant (call rate>0.95, MAF>0.05 and HWE (controls)>0.001) filtering was performed using the SNP & Variation Suite (SVS) v8.3 (Golden Helix, Inc., Bozeman, MT).
To identify genetic variants that contribute to the development of CIO, a stringent Bonferroni multiple testing threshold was calculated based on the inclusion of all variants passing the quality control procedures described above (n=4873) and taking into account the three modes of inheritance (additive, dominant and recessive) that were investigated in the statistical analyses. To reduce excessive Type II errors, arising from sample size limitations that are typical of pharmacogenetic studies, a P value 10-fold above this Bonferroni correction for multiple testing (P<3.4x10 -5 ) was used to prioritize variants for investigation in the replication cohort. Variants associated with CIO in the replication cohort, after Bonferroni correction for multiple testing (P<0.01) (eTable 4.1), were included in the downstream fine-mapping and functional analyses. P values were based on association results obtained using logistic regression analyses including age at time of treatment, cumulative cisplatin dose, cancer protocol and proportion European and East Asian ancestry as covariates. The mode of inheritance used in the statistical analyses is provided in brackets. Shaded areas represent variants that were significant in the discovery cohort, but were not replicated.
Association analyses in the combined cohort
Any variants meeting the criteria for replication were further investigated in the combined cohort. Principal component analyses in this cohort revealed that all individuals of East Asian ancestry were controls (eFigure 3.1). Therefore analyses were repeated removing all individuals of East Asian descent (eTable 4.2). In addition, analyses of the patient clinical characteristics revealed that cases of CIO were older at the start of treatment, received more cycles of cisplatin resulting in higher cumulative cisplatin doses for longer durations and were less likely to receive the BEP treatment protocol (Table 1 ). Pearson's correlation tests revealed that cumulative cisplatin dose was significantly correlated with treatment duration (r=0.84 and r=0.81 in discovery and replication cohorts respectively, P<2.2x10 -16 ) and the number of cycles of cisplatin treatment (r=0.94 and r=0.95 in discovery and replication cohorts respectively, P<2.2x10 -16 ) highlighting that these clinical variables are not independent of one another. The combined cohort was therefore divided up based on the clinical characteristics that were significantly and independently associated with CIO as follows:
i. Age -Engdahl et al 2 report that audiological screening of men above 40 years of age is recommended due to age related hearing impairments. Therefore patients were divided into two categories: young adulthood (<40 years) and middle adulthood (≥40 years) ii.
Cumulative cisplatin dose -The median cumulative dose of cisplatin was 400 mg/m 2 . Therefore patients were divided into two categories: ≥ 400 mg/m 2 and < 400 mg/m 2 iii.
Cancer treatment protocol -The most common treatment protocol that was used was BEP. Therefore patients were divided into two categories: BEP and other Information for the age of one patient was missing and this individual was excluded from these analyses, 2 Regression failed as none of the cases carried rs4788863. P values are based on association results obtained using logistic regression analyses described above, with the characteristic under investigation excluded as a covariate in each of the analyses.
The genotype frequency distribution according to severity of CIO for variants meeting the criteria for replication was further investigated in the combined cohort through the inclusion of individuals experiencing mild CIO (eTable 4.3). HeLa cells were seeded into each well of a 96-well plate in DMEM media supplemented with 10% FBS and 1% L-glutamine and grown overnight at 37°C and 5% CO 2 . The following day, gene silencing was performed using 50nM siGENOME Human SLC16A5 SMARTpool siRNA or siGENOME Non-Targeting siRNA #5 (Dharmacon Lafayette, CO). siRNA transfections were performed using Dharmafect 1 transfection reagent for 24 hours according to the manufacturer's specifications and silencing efficiency was determined by qPCR (ThermoFisher Scientific) (eFigure 6.1).
eFigure 6.1: Silencing of SLC16A5 in HeLa cells using siRNA.
SLC16A5 expression was determined by quantitative PCR following transfection of SLC16A5 or non-targeting siRNA constructs for 24 hours. SLC16A5 expression levels were reduced by approximately 70% under these conditions. Shown are aggregate data (n=6) from 2 independent experiments. *** denotes P<1.0x10 -4 using unpaired student's t-test.
Results
These analyses revealed statistically significant (P<0.01) differences in cell viability between SLC16A5-silenced cells and non-targeting siRNA treated cells at multiple cisplatin concentrations. While SLC16A5-silencing protected cells from lower concentrations of cisplatin [3.16µM (P=7.0x10 -4 ) and 10µM (P=5.4x10 -3 )], this effect was reversed at higher concentrations [31.6µM (P<1.0x10 -4 )] and analysis over a broader range of cisplatin concentrations (316nM-316µM) indicated that the cellular response to cisplatin was significantly different upon SLC16A5-silencing (P<1.0x10 -4 ). This was attributable to a larger magnitude Hill slope for SLC16A5-silenced cells given that the cisplatin IC 50 was similar between silenced and non-silenced treatments (18.75µM vs 18.11µM, respectively) (eTable 6.1). Of note, the differences in cell viability observed upon SLC16A5-silencing at sub-and supra-IC 50 concentrations are reminiscent of the properties associated with a bidirectional transporter, which is in line with the characterization of SLC16A5 transport in a Xenopus system 22, 23 . Future studies quantifying the intracellular effective concentrations of cisplatin may provide further insight into these interactions. 5 HeLa cells were seeded into each well of a 6-well dish in DMEM supplemented with 10% FBS and 1% L-glutamine. The following day, fresh medium containing 0, 10, and 25µM of cisplatin was added to cells, and after 24 hours, total RNA was immediately purified with the Ambion Purelink RNA mini kit using Purelink homogenizers and Purelink on-column DNAse digestion and cDNA was generated using the Invitrogen Superscript III first strand synthesis kit according to the manufacturer's specifications. Real-time RT-PCR (qPCR) experiments of human SLC16A5 and HPRT gene expression in HeLa cells was performed using validated TaqMan assays Hs00757466_s1 and Hs01003267_m1, respectively. qPCR was performed on the PikoReal 96 RealTime PCR system and relative gene expression was calculated with the instrument software by the Cq method using HPRT as a housekeeping gene. To calculate the fold induction of SLC16A5 expression in HeLa cells, the relative SLC16A5 expression in cisplatin-treated cells was divided by relative expression levels in untreated cells. Results were analysed using one-way ANOVA with Tukey post-test analyses (GraphPad, La Jolla, CA).
